Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer ...

In trading on Tuesday, shares of Incyte Corporation (Symbol: INCY) entered into oversold territory, hitting an RSI reading of 27.5, after changing hands as low as $58.16 per share. By comparison ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

Even though the stock has become cheaper, we don't have much confidence in Incyte. Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (BMV:INCY) from Outperform to Market Perform. There are 1,211 funds or institutions reporting positions in ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...

Shares of Incyte stock opened at $60.60 on Friday. The company has a 50-day simple moving average of $69.53 and a two-hundred day simple moving average of $70.04. Incyte has a 52-week low of $50. ...

Peter Parker’s next cinematic outing is officially titled “Spider-Man: Brand New Day.” The fourquel will begin filming this summer, according to director Destin Daniel Cretton, who announced ...